LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS FROM CHINA, BRAZIL, AND SOUTH KOREA WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: RESULTS AT 64 WEEKS

被引：0
|
作者：
Zeng, X. [1 ,2 ]
Zhao, D. [3 ]
Radominski, S. [4 ]
Keiserman, M. [5 ]
Lee, C. K. [6 ]
Martin, N. [7 ]
Meerwein, S. [8 ]
Sui, Y. [9 ]
Park, W. [10 ]
机构：
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp PUMCH, Beijing, Peoples R China
[2] Natl Clin Res Ctr Dermatol & Immunol Dis NCRC DID, Dermatol & Immunol, Beijing, Peoples R China
[3] Shanghai Changhai Hosp, Rheumatol & Immunol, Shanghai, Peoples R China
[4] Univ Fed Parana, Rheumatol, Curitiba, Parana, Brazil
[5] Pontifical Catholic Univ, Rheumatol, Porto Alegre, RS, Brazil
[6] Asan Med Ctr, Rheumatol, Seoul, South Korea
[7] AbbVie Inc, Immunol, Montreal, PQ, Canada
[8] AbbVie Deutsch GmbH & Co KG, Immunol, Ludwigshafen, Germany
[9] AbbVie Inc, Immunol, N Chicago, IL USA
[10] Inha Univ, Sch Med, Rheumatol, Incheon, South Korea
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.1807
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0260
引用
收藏
页码：1156 / 1157
页数：2
相关论文
共 50 条
  • [41] Comprehensive Summary of the Efficacy and Safety of Tofacitinib 5mg Twice Daily in Patients with Rheumatoid Arthritis and an Inadequate Response to Disease-Modifying Antirheumatic Drugs
    Bird, P.
    Bensen, W.
    El-Zorkany, B.
    Kaine, J.
    Manapat-Reyes, B. H.
    Pascual-Ramos, V.
    Witcombe, D.
    Anisfeld, A.
    Soma, K.
    Zhang, R.
    Thirunavukkarasu, K.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S197 - S198
  • [42] The long-term efficacy and safety of disease modifying antirheumatic drugs (DMARD), results of a meta-analysis of 1681 patients with rheumatoid arthritis (RA).
    Keyszer, G
    Keysser, C
    Kruse, R
    Keysser, M
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 475 - 475
  • [43] Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
    van der Heijde, Desiree
    Dougados, Maxime
    Chen, Ying-Chou
    Greenwald, Maria
    Drescher, Edit
    Klar, Rena
    Xie, Li
    de la Torre, Inmaculada
    Rooney, Terence P.
    Witt, Sarah L.
    Schlichting, Douglas E.
    de Bono, Stephanie
    Emery, Paul
    [J]. RMD OPEN, 2018, 4 (01):
  • [44] Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance
    Alla Ishchenko
    Rik J. Lories
    [J]. Drugs & Aging, 2016, 33 : 387 - 398
  • [45] Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance
    Ishchenko, Alla
    Lories, Rik J.
    [J]. DRUGS & AGING, 2016, 33 (06) : 387 - 398
  • [46] A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs
    Klareskog, L.
    Gaubitz, M.
    Rodriguez-Valverde, V.
    Malaise, M.
    Dougados, M.
    Wajdula, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (12) : 1578 - 1584
  • [47] UPADACITINIB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: RESULTS FROM SELECT-NEXT
    Strand, V.
    Pope, J.
    Tundia, N.
    Friedman, A.
    Camp, H. S.
    Pangan, A.
    Ganguli, A.
    Fuldeore, M.
    Goldschmidt, D.
    Schiff, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 989 - 990
  • [48] THE LONG-TERM IMPACT OF FATIGUE ON DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Oliveira, D. Santos
    Martins, A.
    Martins, F. R.
    Samoes, B.
    Rato, M.
    Pinheiro, F. Oliveira
    Nicolau, R.
    Vaz, C.
    Bernardes, M.
    Costa, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1307 - 1307
  • [49] Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Costello, Ruth E.
    Humphreys, Jenny H.
    Winthrop, Kevin L.
    Dixon, William G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (12) : 1665 - 1666
  • [50] Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
    Gulsen Ozen
    Sofia Pedro
    Rebecca Schumacher
    Teresa A. Simon
    Kaleb Michaud
    [J]. Arthritis Research & Therapy, 21
12345